Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether treatment with aliskiren (300 mg)
compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients
with heart failure and normal ejection fraction (HFNEF).
Phase:
Phase 4
Details
Lead Sponsor:
Wake Forest School of Medicine Wake Forest University Health Sciences